The goal of the RTOG Translational Research Program (TRP) is to promote communication of scientific ideas from the research laboratory into RTOG clinical trials by informing the basic science committees on important emerging research in tumor biology, chemical and biological modifiers, and pathology. To that end, specimens derived from RTOG clinical trials are viewed as our most valuable and precious resource, limited and nonrenewable. It is the TRP Committee's highest priority to encourage, optimize and prudently prioritize the use of this resource. To meet this goal RTOG employs a comprehensive application process to allocate biospecimen material. Requests for Application (RFP) are issued for our largest trials.
Requests for Application: RTOG 0617
Biospecimen Availability – Inventory of biospecimens from RTOG clinical trials
Policies/Procedures
Biospecimen Request Procedures – Procedures for submitting an application to use RTOG biospecimens
RTOG Policy on Letters of Support for Grant Funding – Investigators requesting a letter of support (LOS) from RTOG must follow this policy
Forms
RTOG Resource Request Application Form – Investigators requesting biospecimen materials, clinical data, dosimetric data, and/or statistical analysis must submit this form
Biospecimen Feasibility Letter of Intent (LOI) Form – Investigators requesting the use of biospecimen material must submit this form together with their RTOG Resource Request Application Form. The project will receive an initial review for specimen availability and feasibility upon submission of this form. If this initial review is favorable the investigator will be asked to submit a TRP Biospecimen Access Application Form.
TRP Biospecimen Access Application Form– Investigators responding to a posted RTOG RFA or who have received approval of their LOI submit this form to begin the formal review process.
Cooperative Group Banking (CGB) Biospecimen Access Application Form – This form is used to request Biospecimen material from the Cooperative Group Banking repositories.
TRP Committee Liaisons
Chair Adam P. Dicker, MD, PhD, adamdicker@mac.com
Mark W. Dewhirst, DVM, PhD, dewhirst@radonc.duke.edu
Bioinformatics
Ying Xiao, PhD, Chair, ying.xiao@jefferson.edu
Soren Benzon, DSc, PhD, bentzen@humonc.wisc.edu
Brain Tumors
Arnab Chakravarti, MD, arnab.chakravarti@osumc.edu
Kevin Camphausen, MD, camphauk@mail.nih.gov
Paul S. Mischel, MD, PMischel@mednet.ucla.edu
Yaacov Lawrence, MD, yaacovla@gmail.com
Breast Cancer
Wendy Woodward, MD, PhD, wwoodward@mdanderson.org
EORTC
EORTC Eric Deutsch, MD, PhD, eric.deutsch@igr.fr
GI Cancers
Chandan Guha, MD, cguha@montefiore.org
Sunil Krishnan, MD, skrishnan@mdanderson.org
GU Cancer
Felix Feng, MD, ffeng@med.umich.edu
Alan Pollack, MD, PhD, APollack@med.miami.edu
GYN Oncology
Joanne Weidhaas, MD, PhD, Joanne.Weidhaas@yale.edu
Head & Neck Cancers
Christine H. Chung, MD, cchung11@jhmi.edu
IGRT
Laura Dawson, MD, laura.dawson@rmp.uhn.on.ca
Lung Cancer
Bo Lu, MD, Bo.Lu@jeffersonhospital.org
Joe Y. Chang, MD, PhD, JYChang@mdanderson.org
Feng-Ming (Spring) Phoenix Kong, MD, PhD, FengKong@umich.edu
Zhongxiang Liao, MD, zliao@mdanderson.org
Normal Tissue Effects
Deborah Citrin, MD, Citrind@mail.nih.gov
Barry Rosenstein, PhD, Barry.Rosenstein@mssm.edu
Outcomes / QoL
Deborah Citrin, MD, Citrind@mail.nih.gov
Adam P. Dicker, MD, PhD, adamdicker@mac.com
Proton Therapy
Jason Efstathiou, MD, PhD, jefstathiou@partners.org
Publications
Arnab Chakravarti, MD, arnab.chakravarti@osumc.edu
Adam P. Dicker, MD, PhD, adamdicker@mac.com
Sarcoma
William Kraybill, MD, William.Kraybill@osumc.edu
David Guy Kirsch, MD, PhD, david.kirsch@duke.edu
Biospecimen Resource
Richard Jordan, DDS, PhD, Richard.jordan@ucsf.edu
Trans-Canada Translational Research
Robert G. Bristow, MD, PhD, rob.bristow@rmp.uhn.on.ca